DocGo Q4 Revenue at $74.9M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy DCGO?
Reports Q4 revenue $74.9M, consensus $70.4M. Lee Bienstock, Chief Executive Officer of DocGo, commented "While 2025 was a year of transition and focus on our core business lines, the robust growth in our 'healthcare at any address' business - which includes care in the home, remote patient monitoring, mobile phlebotomy and virtual care services - supports our belief that DocGo's offering is well positioned to meet the needs of the evolving healthcare landscape." Bienstock continued "We are increasing guidance based on the record volumes we've seen thus far in 2026, and the anticipated full-year impact of our cost efficiency initiatives. We believe that our plan and resources are sufficient to enable the Company to achieve profitability in the second half of 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DCGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DCGO
Wall Street analysts forecast DCGO stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.600
Low
1.50
Averages
3.13
High
4.00
Current: 0.600
Low
1.50
Averages
3.13
High
4.00
About DCGO
DocGo Inc. is a mobile healthcare services company that uses dispatch and communication technology to help provide mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations and healthcare transportation in major metropolitan cities in the United States and the United Kingdom. The Company’s offerings also include mobile phlebotomy lab services, which is engaged in addressing critical gaps in diagnostic care for underserved populations. The Mobile Health Services include a variety of healthcare services performed at homes, offices and other locations and event services, such as on-site healthcare support at sporting events and concerts. The Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DocGo Recognized as One of the 2026 World's Most Ethical Companies
- Ethical Recognition: DocGo Inc. has been honored by Ethisphere as one of the 2026 World's Most Ethical Companies, highlighting the company's exceptional performance in ethics and compliance within the healthcare sector, thereby enhancing its reputation and competitive edge in the industry.
- Industry Leadership: As one of only four honorees in the healthcare providers category, DocGo's recognition among 138 awardees underscores its unique position and further solidifies its leadership in the medical technology field.
- Governance and Compliance Strengthening: Chief Compliance Officer Stephen Sugrue emphasized that DocGo's efforts in governance, risk, and compliance have made ethical behavior central to daily decision-making, improving overall operational efficiency and employee satisfaction.
- Commitment to Continuous Improvement: CEO Lee Bienstock stated that the company will continue to focus on strong governance and transparency to ensure that ethics and integrity remain paramount in the rapidly evolving healthcare landscape, thus driving long-term business success.
See More
DocGo Inc. Reports Q4 2025 Earnings Highlights
- Revenue Performance: DocGo reported $74.9 million in Q4 2025 revenue, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects, highlighting the challenges and opportunities in the company's transformation process.
- EBITDA Loss Improvement: The adjusted EBITDA loss was $11.6 million, with management projecting a reduction to $5 million to $10 million in 2026, reflecting positive progress in cost control and operational efficiency.
- SteadyMD's Strong Performance: SteadyMD exceeded $8 million in revenue for the first time in Q4, driving overall revenue growth and expected to continue as a key growth driver for the company in 2026.
- Exploration of Strategic Alternatives: DocGo has initiated a process to explore various strategic alternatives aimed at maximizing shareholder value, demonstrating management's proactive approach to future developments and sensitivity to market changes.
See More
DocGo (DCGO) Q4 2025 Earnings Call Transcript
See More
DocGo Q4 Earnings Report Analysis
- Disappointing Earnings: DocGo reported a Q4 GAAP EPS of -$1.37, missing estimates by $1.23, indicating a significant decline in profitability that could negatively impact investor confidence.
- Revenue Performance: The total revenue for Q4 was $74.9 million, beating expectations by $4.54 million, although overall performance still lags behind last year, reflecting growth potential in specific business areas.
- Widening Net Loss: The net loss for Q4 reached $142.3 million, a substantial increase from $7.6 million in the same quarter last year, primarily due to $78 million in non-cash items, highlighting challenges in asset management.
- Cash Flow Situation: As of December 31, 2025, the company held approximately $68.3 million in cash and cash equivalents, a significant drop from $95.2 million as of September 30, 2025, reflecting liquidity pressure from the acquisition of SteadyMD and related transaction payments.
See More
Halper Sadeh LLC Investigates DocGo Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC is investigating whether DocGo Inc. executives breached their fiduciary duties, allowing shareholders to seek legal remedies within a limited timeframe to ensure corporate governance reforms and fund recovery.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders are not responsible for upfront legal costs, which reduces the financial burden of pursuing rights and encourages broader shareholder participation.
- Transparency Enhancement: By involving shareholders, Halper Sadeh LLC aims to improve the company's policies and oversight mechanisms, thereby increasing transparency and accountability, ultimately enhancing shareholder value.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its strength in protecting investor rights.
See More
DocGo to Release Q4 and Full Year 2025 Financial Results on March 16, 2025
- Earnings Release Schedule: DocGo will announce its fourth quarter and full year financial results for the period ending December 31, 2025, after market close on March 16, 2025, highlighting the company's performance in medical transportation and mobile health services.
- Conference Call Details: Management will host a conference call at 5:00 p.m. ET on the same day to discuss the financial results and outlook for 2026, which is expected to attract investor and analyst attention, enhancing the company's transparency.
- Innovative Healthcare Platform: DocGo's technology-enabled medical transportation and mobile health services aim to reshape the traditional healthcare system by providing high-quality, accessible care that enhances patient experience and strengthens market competitiveness.
- Telehealth Integration: DocGo's mobile health services facilitate patient treatment in collaboration with remote physicians, enabling care in the comfort of patients' homes or workplaces, and seamlessly bridging physical and virtual care through its medical transport services, thereby improving overall healthcare efficiency.
See More
DocGo Recognized as One of the 2026 World's Most Ethical Companies
- Ethical Recognition: DocGo Inc. has been honored by Ethisphere as one of the 2026 World's Most Ethical Companies, highlighting the company's exceptional performance in ethics and compliance within the healthcare sector, thereby enhancing its reputation and competitive edge in the industry.
- Industry Leadership: As one of only four honorees in the healthcare providers category, DocGo's recognition among 138 awardees underscores its unique position and further solidifies its leadership in the medical technology field.
- Governance and Compliance Strengthening: Chief Compliance Officer Stephen Sugrue emphasized that DocGo's efforts in governance, risk, and compliance have made ethical behavior central to daily decision-making, improving overall operational efficiency and employee satisfaction.
- Commitment to Continuous Improvement: CEO Lee Bienstock stated that the company will continue to focus on strong governance and transparency to ensure that ethics and integrity remain paramount in the rapidly evolving healthcare landscape, thus driving long-term business success.
See More
DocGo Inc. Reports Q4 2025 Earnings Highlights
- Revenue Performance: DocGo reported $74.9 million in Q4 2025 revenue, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects, highlighting the challenges and opportunities in the company's transformation process.
- EBITDA Loss Improvement: The adjusted EBITDA loss was $11.6 million, with management projecting a reduction to $5 million to $10 million in 2026, reflecting positive progress in cost control and operational efficiency.
- SteadyMD's Strong Performance: SteadyMD exceeded $8 million in revenue for the first time in Q4, driving overall revenue growth and expected to continue as a key growth driver for the company in 2026.
- Exploration of Strategic Alternatives: DocGo has initiated a process to explore various strategic alternatives aimed at maximizing shareholder value, demonstrating management's proactive approach to future developments and sensitivity to market changes.
See More
DocGo (DCGO) Q4 2025 Earnings Call Transcript
See More
DocGo Q4 Earnings Report Analysis
- Disappointing Earnings: DocGo reported a Q4 GAAP EPS of -$1.37, missing estimates by $1.23, indicating a significant decline in profitability that could negatively impact investor confidence.
- Revenue Performance: The total revenue for Q4 was $74.9 million, beating expectations by $4.54 million, although overall performance still lags behind last year, reflecting growth potential in specific business areas.
- Widening Net Loss: The net loss for Q4 reached $142.3 million, a substantial increase from $7.6 million in the same quarter last year, primarily due to $78 million in non-cash items, highlighting challenges in asset management.
- Cash Flow Situation: As of December 31, 2025, the company held approximately $68.3 million in cash and cash equivalents, a significant drop from $95.2 million as of September 30, 2025, reflecting liquidity pressure from the acquisition of SteadyMD and related transaction payments.
See More
Halper Sadeh LLC Investigates DocGo Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC is investigating whether DocGo Inc. executives breached their fiduciary duties, allowing shareholders to seek legal remedies within a limited timeframe to ensure corporate governance reforms and fund recovery.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders are not responsible for upfront legal costs, which reduces the financial burden of pursuing rights and encourages broader shareholder participation.
- Transparency Enhancement: By involving shareholders, Halper Sadeh LLC aims to improve the company's policies and oversight mechanisms, thereby increasing transparency and accountability, ultimately enhancing shareholder value.
- Global Investor Support: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its strength in protecting investor rights.
See More
DocGo to Release Q4 and Full Year 2025 Financial Results on March 16, 2025
- Earnings Release Schedule: DocGo will announce its fourth quarter and full year financial results for the period ending December 31, 2025, after market close on March 16, 2025, highlighting the company's performance in medical transportation and mobile health services.
- Conference Call Details: Management will host a conference call at 5:00 p.m. ET on the same day to discuss the financial results and outlook for 2026, which is expected to attract investor and analyst attention, enhancing the company's transparency.
- Innovative Healthcare Platform: DocGo's technology-enabled medical transportation and mobile health services aim to reshape the traditional healthcare system by providing high-quality, accessible care that enhances patient experience and strengthens market competitiveness.
- Telehealth Integration: DocGo's mobile health services facilitate patient treatment in collaboration with remote physicians, enabling care in the comfort of patients' homes or workplaces, and seamlessly bridging physical and virtual care through its medical transport services, thereby improving overall healthcare efficiency.
See More
